Otonomy Stock Forecast, Price & News

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

Is Otonomy a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Otonomy stock.
View analyst ratings for Otonomy or view top-rated stocks.

What stocks does MarketBeat like better than Otonomy?

Wall Street analysts have given Otonomy a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Otonomy wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Otonomy's next earnings date?

Otonomy is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Otonomy.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) announced its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The biopharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.07 million. Otonomy had a negative net margin of 20,278.95% and a negative trailing twelve-month return on equity of 67.24%.
View Otonomy's earnings history.

How has Otonomy's stock price been impacted by Coronavirus (COVID-19)?

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has decreased by 23.7% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for OTIC?

2 Wall Street analysts have issued 12 month price targets for Otonomy's stock. Their forecasts range from $5.50 to $11.00. On average, they anticipate Otonomy's share price to reach $7.50 in the next year. This suggests a possible upside of 275.0% from the stock's current price.
View analysts' price targets for Otonomy or view top-rated stocks among Wall Street analysts.

Who are Otonomy's key executives?

Otonomy's management team includes the following people:

• David A. Weber, President, Chief Executive Officer & Director
• Paul E. Cayer, Chief Financial & Business Officer
• Fabrice Piu, Vice President-Research & Preclinical Development
• Robert Michael Savel, Chief Technical Officer
• Alan C. Foster, Vice President-Research

Who are some of Otonomy's key competitors?

Some companies that are related to Otonomy include Chimerix (CMRX), Altimmune (ALT), Viking Therapeutics (VKTX), Greenwich LifeSciences (GLSI), Evolus (EOLS), Nanobiotix (NBTX), VistaGen Therapeutics (VTGN), AC Immune (ACIU), XBiotech (XBIT), Werewolf Therapeutics (HOWL), Evelo Biosciences (EVLO), eFFECTOR Therapeutics (EFTR), Kezar Life Sciences (KZR), Marinus Pharmaceuticals (MRNS) and Relmada Therapeutics (RLMD).
View all of OTIC's competitors.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.00.

How much money does Otonomy make?

Otonomy has a market capitalization of $113.36 million and generates $270,000.00 in revenue each year. The biopharmaceutical company earns $-44.73 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Otonomy have?

Otonomy employs 56 workers across the globe.

What is Otonomy's official website?

The official website for Otonomy is www.otonomy.com.

Where are Otonomy's headquarters?

Otonomy is headquartered at 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (619) 323-2200 or via email at [email protected].